PE0116 Injection in Treatment of Patients With Advanced Solid Tumours

Locally Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
A Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients With Advanced Solid Tumor

Status Completed

Clinical Trial Summary

This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Locally Advanced/Metastatic Solid Tumors
Neoplasms

Clinical Trial Details

NCT number	NCT05800249
Study type	Interventional
Source	Shanghai HyaMab Biotech Co.,Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	March 8, 2021
Completion date	June 16, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05801237` - PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor	Phase 1/Phase 2
Active, not recruiting	`NCT06130722` - First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study	Phase 1
Completed	`NCT04914351` - HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours	Phase 1
Not yet recruiting	`NCT06414460` - Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT04294576` - Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors	Phase 1